|
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial Clinical research trials and Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial. Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial clinical trial. Subjects frequently obtain the most expert healthcare possible for their Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "L" Clinical Trials Conditions > Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial  Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial
For Condition: Asthma,Lung Diseases
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To elucidate the mechanisms underlying inter-patient variation in response to montelukast, a drug for asthma.
Details: BACKGROUND: Asthma is a common disease caused by a complex interaction between genetic and environmental factors. Asthma afflicts 17 million Americans. In 1999, more than 5000 persons died from asthma. Given the significant mortality and morbidity associated with asthma, it is important to continue to develop new strategies for intervention. Leukotriene antagonists are thought to be the most innovative approach to asthma therapy in 20 years. Despite their demonstrated efficacy, safety and popularity, the leukotriene antagonists are associated with a significant degree of inter-patient variability in response, which can limit their safety, efficacy and cost-effectiveness. Several polymorphisms in leukotriene pathway genes can contribute to variability in response. The project will determine if polymorphisms in genes encoding 5-lipoxygenase, leukotriene A4hydrolase, LTC4 synthase, multi-drug resistance protein 1 (MRP1) and LT1 receptor proteins are determinants of response to montelukast treatment. The study is in response to an Request for Applications entitled Ancillary Studies in Heart, Lung, and Blood Disease Trials which was released by the NHLBI in June 2000 to conduct mechanistic studies in clinical trials related to heart, lung and blood diseases. Specifically, this initiative focuses on the utilization of patients and patient materials from such trials to study the mechanisms underlying the interventions, the mechanisms of disease pathogenesis, surrogate markers or biomarkers of disease activity and therapeutic effect and the mechanisms of human cardiopulmonary and hematologic function. Studies aimed at accelerating the development of new technologies within the context of the mechanistic investigations are also encouraged. DESIGN NARRATIVE: DNA will be collected from patients participating in a parent clinical trial entitled: Effectiveness of Low Dose Theophylline as Add-On Therapy in the Treatment of Asthma (LoDo Trial). 627 patients from 19 Asthma Clinical Research Centers will be randomly assigned to receive placebo, or low dose theophylline (300 mg/day) or montelukast, 10 mg daily, for 6 months. Stepwise Linear and Poisson regressions will be performed on outcomes including treatment and genetic covariates, and interaction terms between treatment arm and genetic makeup. Polymorphisms that are highly associated with response can lead to the development of genetic tests that will identify patients most likely to benefit from montelukast treatment. This information may lead to individualization of asthma medications based on the genetic make-up of the patient.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
JohnLima, , Nemours Children's Clinic
Additional Information:
Study ID Numbers: 1189;
Study Start Date: June 2002
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046644
Other Asthma Studies:
1. Intervention to Improve Asthma Management/Prevention
2. Childhood Asthma Management Program (CAMP) Phases I and II
3. Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT
4. Activation and Function of Eosinophils in Conditions with Blood or Tissue Eosinophilia
5. FLASH Study: A study of roflumilast versus placebo in patients with asthma
Related Studies:
Other Asthma Clinical Trials
Other Clinical Trials
Other Clinical Trials
Leukotriene Polymorphisms and Montelukast Response - Ancillary to LoDo Trial
|
|
|
|
|
|
|
|
